Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

The infected woman, who is hospitalized, was likely exposed to H5N1 through contact with her infected backyard poultry flock.

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...